Oramed Pharmaceuticals Inc.
(ORMP) – NasdaqCM

3.38
0.01 (0.15%)
Refresh Quote
Exchange :NASDAQ (US Dollar)
Ric Code :ORMP
Volume :118,605
Date :07-09-2020

* Minimum 20 minute delay See terms

Oramed Pharmaceuticals (NASDAQ: ORMP) has developed innovative technology to transform injectable treatments into oral therapies.

Oramed’s flagship product, an oral insulin capsule, can better the lives of millions of diabetics around the world – allowing, amongst other things, type 2 patients to begin insulin therapy earlier without fear of needles… [READ MORE >]

Oramed Announces Positive Initial Clinical Trial Results for Treatment of NASH With Oral Insulin

June 15th, 2020|Comments Off on Oramed Announces Positive Initial Clinical Trial Results for Treatment of NASH With Oral Insulin

Data Presented at the American Diabetes Association Scientific Session 2020 NEW YORK, June 15, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug [...]

Oramed Pharmaceuticals to Present at the 80th American Diabetes Association Scientific Session, to be Held Virtually This Year in June

May 5th, 2020|Comments Off on Oramed Pharmaceuticals to Present at the 80th American Diabetes Association Scientific Session, to be Held Virtually This Year in June

Three Poster Presentations Granted to Discuss Oral Insulin Candidate ORMD-0801 NEW YORK, May 5, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug [...]

Oramed Patent in Canada Allowed for Oral Delivery of Proteins

April 7th, 2020|Comments Off on Oramed Patent in Canada Allowed for Oral Delivery of Proteins

NEW YORK, April 7, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Canadian Patent Office [...]

Oramed Pharmaceuticals Issues CEO Shareholder Letter Providing Business Update Amid COVID-19

April 1st, 2020|Comments Off on Oramed Pharmaceuticals Issues CEO Shareholder Letter Providing Business Update Amid COVID-19

- Oral insulin FDA End-of-Phase 2 meeting expected this quarter - Strong balance sheet with roughly $50M in cash - NASH intermediate study data expected this quarter NEW YORK, April 1, 2020 /PRNewswire/ -- Oramed Pharmaceuticals [...]